GSK PLC

GSK

Healthcare|Drug Manufacturers - General|UK

$52.78

+0.31 (+0.59%)

DCF (FCF)

$40.01

Earnings Power

$32.61

Upcoming Data Readouts (3)

Mar 2027

Est. completion

P1Gastrointestinal Neoplasms

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

Oct 2027

Est. completion

P1P2Ovarian Clear Cell Carcinoma

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

Jul 2028

Est. completion

P2Cervical Cancer

TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation

Trials past primary completion date but still active — data readout may be imminent.

Jun 2026

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Dec 2025

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough